ArticleChinese journal of cancer2017

Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma.

Wen Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.